We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Sequencing System Increases Data Production While Reducing Costs.

By LabMedica International staff writers
Posted on 27 Jan 2010
Researchers engaged in human genome sequencing and profiling will benefit from the introduction of a new, low cost, high output system.

The new instrument, the Illumina Inc. More...
(San Diego, CA, USA) HiSeq 2000, is capable of generating two billion paired-end reads and 200 gigabases (Gb) of quality filtered data in a single run. The system uses two flow cells and an innovative dual-surface imaging method, enabling new levels of sequencing output as well as experimental flexibility.

For the operator the HiSeq 2000 offers streamlined and intuitive single operator workflow; initiating a run requires less than 10 minutes total hands-on time. Preconfigured plug-and-play reagents, a touch screen user interface, and real-time and remote run monitoring result in simpler instrument operation. Jay Flatley, president and CEO of Illumina, said, "These innovations redefine the trajectory of sequencing and, for the first time, take the cost of sequencing a human genome below $10,000."

"HiSeq will have a major impact on a broad range of applications, including advancing our understanding of cancer and other complex genetic diseases. We can now sequence two human genomes in a single run--for example, a tumor and a normal sample--at 30-fold coverage," said Dr. David Bentley, vice president and chief scientist at Illumina. "The unprecedented output and cost-effective operation will make human genome sequencing routine and allow researchers to easily compare entire genomes, transcriptomes, and epigenomes."

The HiSeq 2000 sequencing system began shipping in limited quantities to selected sites in February 2009, and is expected to ship broadly in March 2010.

Related Links:

Illumina Inc.



New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automated Urinalysis Solution
UN-9000
New
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The method that profiles DNA methylation in cell-free DNA from a single blood sample to detect disease signals system-wide (photo courtesy of Shutterstock)

cfDNA Methylation Assay Enables Multi-Disease Detection from Single Blood Sample

Early, accurate detection of cancer and organ disease remains limited by cost, reliance on targeted mutation assays, and uncertainty about the signal’s tissue of origin. Many liquid biopsy approaches require... Read more

Immunology

view channel
Image: Mycobacterium tuberculosis bacteria seen with a scanning electron microscope (Credit: CDC PHIL)

Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection

Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.